The two companies will collaborate on selling Calcichew products until the end of 2013, when Takeda will take over full marketing responsibility.
Calcichew products are prescribed as an adjunctive therapy for vitamin D and/or calcium deficiency in pregnancy and in patients with osteoporosis or malnutrition.
Shire and Takeda will share commercial activity in 2013, with Shire responsible for sales and distribution of Calcichew and Takeda for promotion and marketing.
Marketing authorisation will transfer to Takeda in January 2014. The financial details remain confidential.
“This is an exciting development for Takeda in the UK and Ireland,” said Yasuhiro Fukutomi, Managing Director of Takeda UK. “The Calcichew portfolio will add significant financial revenues to Takeda in the UK and Ireland and there is significant potential for growth in both countries.
“We have successfully repatriated other products to Takeda UK over the last three years and we will work to repeat this success with the Calcichew portfolio. We look forward to working collaboratively with Shire to achieve a smooth transition that will ensure continued support and an uninterrupted product supply for healthcare professionals and patients.”
Based in Norway, Takeda Nycomed is an affiliate of the Japanese company Takeda Pharmaceutical, which acquired Nycomed in 2011.